Advocacy at a Glance
Advocacy at a Glance offers you the bullet point summary of current advocacy issues associated with the goals of the Alliance for a Stronger FDA.
- CDRH Director Shuren’s Presentation Well Received. The Alliance’s quarterly meeting was held this week in Washington and the featured speaker was CDRH director Jeff Shuren. Copies of his slides are attached.
- Congress Returns; Still Deciding Fate of FY 17 Spending. Next week, the Senate is likely to consider a Continuing Resolution that extends government funding from October 1 until December 9. The level will be set at the FY 16 spending rate. If an agreement can be reached on a Zika funding bill (minus poison pill amendments), there is a chance it will be added to the Senate version of the CR.
The House position is still in flux. House Conservatives appear to favor a longer-term CR, possibly 6 months until March 31, 2017 and they would set it at the FY 16 spending level or less. Some of those advocating for the longer CR have said they would consider a shorter one if there was concession on some policy issue(s) (e.g., temporarily halting Syrian refugee entry into the US). Speaker of the House Paul Ryan will be caught in the middle as he tries to negotiate with members of his own caucus.
- FDA Hurt By Continuing Resolution; Helped by Omnibus or Minibus. Based on House and Senate mark-ups, FDA is due for almost a 1.5% increase in appropriated funds for FY 17. Under a Continuing Resolution, the agency could only spend at its FY 16 level, negating the increase for as long as the CR is in place. FDA’s situation is explained in more detail in this week’s Analysis and Commentary.